The results of a clinical study in Norway entitled
"Hydroxycitrate (HCA) in the Treatment of Obesity" will be presented at the European Congress on Obesity to be held in Barcelona, Spain May 14 - 17, 1996. The study, conducted by Erling Thom at Medstat Research in Norway, used Citrin® , a product of the Sabinsa Corporation, as the exclusive source of HCA.
Sixty-six patients with obesity were included in a randomized, placebo-controlled double-blind study lasting 8 weeks which incorporated a low-fat diet and exercise three times weekly. The mean weight reduction in the HCA group was 14. 11 lbs., and in the placebo group was 8.37 lbs. The difference in weight reduction is statistically significant (p < 0.001).
The study concluded that it "is an effective and well tolerated short-term treatment of overweight and obesity when combined with a low-fat diet and exercise." The participants will be followed regularly for 12 months in an open follow up study where all patients will receive Citrin as the source of HCA.
HCA was first made available in the U.S. by Sabinsa Corporation in 1991 under the trademarked name Citrin. Citrin, the first all natural derivative of Garcinia Cambogia ever introduced to the U.S. market, has been shown through independent laboratory analysis to contain the highest percentage of lactone-free hydroxycitric acid.
